Abstract 2063
Background
ATR inhibitors (ATRi) are in early phase clinical trials and have been shown to sensitise to chemotherapy and radiotherapy (RT) in preclinical data. No data have been published about the effect of these drugs on the tumour microenvironment. We demonstrate significant modulation of the immune microenvironment by ATRi + RT.
Methods
We used an immunocompetent mouse model of HPV-driven malignancies (TC1) to investigate the effect of the ATRi, AZD6738, in combination with RT 8 Gy in 4 fractions. Gene expression analysis, flow cytometry and cytokine quantification were used.
Results
There was sensitisation to RT by ATRi in this model. ATRi + RT caused a marked increase in a number of adaptive immune cells infiltrating the tumour at 5 days after treatment. There were significantly more dendritic cells, macrophages, and myeloid-derived suppressor cells after ATRi + RT. We also identified increased numbers of CD3+ and NK cells after the combination treatment. Transcriptional analysis found evidence of increased T-cell activation with the combination therapy. We found evidence of an interferon (IFN) response, with transcriptional upregulation of IFN-stimulated genes including those playing a role in nucleic acid sensing: Ddx58/RIG-I, and Ifih1/MDA5, Zbp1/DAI and Ddx60. We identified significant modulation of cytokine gene expression (CCL2, CCL5, CXCL10), and found that cultured tumour cells secreted CCL3, CCL5 and CXCL10 after ATRi + RT. We hypothesise that DNA damage and micronucleus formation caused by ATR + RT (as previously reported by us, Dillon et al. MCT 2016;16:25-34) leads to an IFN response through activation of nucleic acid sensing pathways, leading to influx of innate immune cells.
Conclusions
To our knowledge this is the first comprehensive analysis of the immune tumour microenvironment after radiation with a radiosensitising targeted drug. Further understanding of the effect of this combination on immune response may allow modulation to maximise tumour control through activation of anti-tumour immunity. MTD is a CRUK clinical research fellow. AZD6738 provided by AstraZeneca. MM, KJH joint senior authors.
Clinical trial identification
Legal entity responsible for the study
The Institute of Cancer Research.
Funding
Cancer Research UK.
Editorial Acknowledgement
Disclosure
M.T. Dillon: Co-investigator on clinical study of AZD6738 which is partially funded by AstraZeneca. A. Melcher: Compensated consultant/advisor and received honoraria: Amgen, BMS, Merck Serono; Research funding: Oncolytics Biotech Inc. K.J. Harrington: Payment for consulting fees: Amgen, AstraZeneca/Medimmune, BMS, Lytix Biopharma, MSD, Merck, Oncos Therapeutics, Pfizer, Viralytics Inc.; Research grant funding: MSD, Oncolytics Biotech., Viralytics Inc. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract